Updated Oct 23, 2026
/Kustom Entertainment increases authorized shares to 1.2 billion/ORIC Targets 2027 Phase 3 Trial for Enozertinib After ESMO Data/Autoliv Q3 net sales fall 0.5% to $2,693 million/Zymeworks signs global deal with Roche for ZW209/Tango Therapeutics files 8-K for PDAC investor presentation/UY SCUTI Acquisition Corp. issues two unsecured promissory notes/Kustom Entertainment increases authorized shares to 1.2 billion/ORIC Targets 2027 Phase 3 Trial for Enozertinib After ESMO Data/Autoliv Q3 net sales fall 0.5% to $2,693 million/Zymeworks signs global deal with Roche for ZW209/Tango Therapeutics files 8-K for PDAC investor presentation/UY SCUTI Acquisition Corp. issues two unsecured promissory notes
NewsSOS
Contact

Talk to the newsroom.

Tips, corrections, partnerships, press. Pick the lane that fits.

01

General contact

For feedback, corrections, syndication, partnerships, or anything that doesn't need the tip line.

02

Submit a tip

You saw it first?

Seen something we should cover? Send what you know, and a link to anything on the record.

  • → Source anonymity protected
03

Press inquiries

For media & press contacts.

Comment requests, syndication, and licensing.

How to reach us
Use the contact form ↑

Put “Press” plus your outlet, deadline, and topic in the subject line.

04

The newsletter

Be the first to know.

One email when something big publishes — unsubscribe in a tap, no digest, no noise.

Sent only when it matters

We never share your address. Sign-up is the only thing that lands in your inbox.